![conference banner](/images/conference-banner.jpeg)
Abstract
Background: Total HIV-DNA load in peripheral blood cell (PBMCs) reflects the global viral reservoir that seems not to be affected by antiretroviral treatment. However, some studies reported a different permeability of different drugs in cellular compartments.
Objective: To investigate the relation between the amount of total HIV-1 DNA and different treatment strategies.
Methods: Total HIV-1 DNA was quantified by real time PCR in PBMCs collected from 161 patients with long-term undetectable HIV-RNA receiving different therapy schedules (3-drug regimens or 2-drug regimen containing Raltegravir as integrase inhibitor).
Results: Overall, HIV patients who started therapy with a median pre-ART CD4+ cell count >400 cells/mm3 and HIV viral load of 3 log10 copies/ml, achieved a lower amount of HIV total DNA. No significant correlation was found in DNA size when patients were stratified on the basis of different therapeutic protocols. However, HIV DNA load analysis, when only performed in HIV patients with a median pre-ART CD4+ cell count >200 cells/mm3 and HIV viral load < 3 log10 copies/ml, showed a significative DNA decrease in Raltegravir treated group with respect to the NNRTIs-treated group.
Conclusion: The data emphasize that HIV-DNA level represents a predictive factor in long-term suppressive therapy patients. In addition, the diminished reservoir, only observed in patients treated with the NRTI-sparing regimen RAL plus PI/r before immunological and virological derangement, suggests that latest generation drugs, such as integrase inhibitors, might represent an optimal chance in the management of HIV infection.
Keywords: HIV-1 DNA, HIV-RNA, CD4+ cells, antiretroviral therapy, reservoir, NRTI-sparing regimen.
Current HIV Research
Title:Impact of Different Antiretroviral Strategies on Total HIV-DNA Level in Virologically Suppressed HIV-1 Infected Patients
Volume: 15 Issue: 6
Author(s): Isabella Bon, Leonardo Calza, Giuseppina Musumeci, Serena Longo, Alessia Bertoldi, Vanessa D`Urbano, Davide Gibellini, Eleonora Magistrelli, Pier Luigi Viale and Maria Carla Re*
Affiliation:
- Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine, University of Bologna, Bologna, Italy, Via Massarenti 9-40138 Bologna,Italy
Keywords: HIV-1 DNA, HIV-RNA, CD4+ cells, antiretroviral therapy, reservoir, NRTI-sparing regimen.
Abstract: Background: Total HIV-DNA load in peripheral blood cell (PBMCs) reflects the global viral reservoir that seems not to be affected by antiretroviral treatment. However, some studies reported a different permeability of different drugs in cellular compartments.
Objective: To investigate the relation between the amount of total HIV-1 DNA and different treatment strategies.
Methods: Total HIV-1 DNA was quantified by real time PCR in PBMCs collected from 161 patients with long-term undetectable HIV-RNA receiving different therapy schedules (3-drug regimens or 2-drug regimen containing Raltegravir as integrase inhibitor).
Results: Overall, HIV patients who started therapy with a median pre-ART CD4+ cell count >400 cells/mm3 and HIV viral load of 3 log10 copies/ml, achieved a lower amount of HIV total DNA. No significant correlation was found in DNA size when patients were stratified on the basis of different therapeutic protocols. However, HIV DNA load analysis, when only performed in HIV patients with a median pre-ART CD4+ cell count >200 cells/mm3 and HIV viral load < 3 log10 copies/ml, showed a significative DNA decrease in Raltegravir treated group with respect to the NNRTIs-treated group.
Conclusion: The data emphasize that HIV-DNA level represents a predictive factor in long-term suppressive therapy patients. In addition, the diminished reservoir, only observed in patients treated with the NRTI-sparing regimen RAL plus PI/r before immunological and virological derangement, suggests that latest generation drugs, such as integrase inhibitors, might represent an optimal chance in the management of HIV infection.
Export Options
About this article
Cite this article as:
Bon Isabella, Calza Leonardo, Musumeci Giuseppina , Longo Serena , Bertoldi Alessia , D`Urbano Vanessa , Gibellini Davide , Magistrelli Eleonora , Viale Luigi Pier and Re Carla Maria*, Impact of Different Antiretroviral Strategies on Total HIV-DNA Level in Virologically Suppressed HIV-1 Infected Patients, Current HIV Research 2017; 15 (6) . https://dx.doi.org/10.2174/1570162X16666171206121026
DOI https://dx.doi.org/10.2174/1570162X16666171206121026 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV Vaccine Development.
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in People Living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Large Conductance Calcium- and Voltage-activated Potassium Channel (BK) and Epilepsy
CNS & Neurological Disorders - Drug Targets Towards Newer Molecular Targets for Chronic Diabetic Complications
Current Vascular Pharmacology Contribution of Platelet-Derived CD40 Ligand to Inflammation, Thrombosis and Neoangiogenesis
Current Medicinal Chemistry The Plasma and Tissue Kininogen-kallikrein-kinin System: Role in the Cardiovascular System
Current Medicinal Chemistry - Cardiovascular & Hematological Agents A Review on Subcutaneous Veins Localization Using Imaging Techniques
Current Medical Imaging WITHDRAWN: Insights into the Biological Properties of Prostate Cancer Stem Cells: Implications for Cancer Progression and Therapy
Current Stem Cell Research & Therapy Altering the Tropism of Lentiviral Vectors through Pseudotyping
Current Gene Therapy Molecular Advances Toward the Understanding of the Patho-Biology of Idiopathic Myelofibrosis
Current Immunology Reviews (Discontinued) Nanocarriers for Effective Topical Delivery of Anti-Infectives
Current Nanoscience Clinical Studies with Paclitaxel - Eluting Stent Systems
Current Pharmaceutical Design Multivalent & Multifunctional Ligands to β-Amyloid
Current Pharmaceutical Design The Contribution of Cerebral Vascular Neuropathology to Mild Stage of Alzheimer’s Dementia Using the NACC Database
Current Alzheimer Research Imaging Studies in Hypercalcemia
Current Medicinal Chemistry Impaired Renal Function and Biomarkers of Vascular Disease in Alzheimer’s Disease
Current Alzheimer Research The Nitric Oxide Signaling Pathway in the Penis
Current Pharmaceutical Design Recent Advances in Drug Repurposing for Parkinson’s Disease
Current Medicinal Chemistry Microvascular Diseases: Is A New Era Coming?
Cardiovascular & Hematological Agents in Medicinal Chemistry Contemporary Review of Drugs Used to Treat Obesity
Cardiovascular & Hematological Agents in Medicinal Chemistry Serum S-100B Protein as A Biochemical Marker of Brain Injury: A Review of Current Concepts
Current Medicinal Chemistry Metabolic Activation of Herbal and Dietary Constituents and Its Clinical and Toxicological Implications: An Update
Current Drug Metabolism